Zacks Rank Education -- Learn more about the Zacks Rank These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Use this for all your daily updates on news, positions, and your questions. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. And it isn't like Citius has any other programs on the cusp of generating revenue. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Created Feb 16, 2021. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. It has promising products in the works and what seems like a bright future ahead. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Research, Inc. nor its Information Providers can guarantee the accuracy, Welcome to the CTXR Daily Discussion Thread! By mid-March, the shares had retraced to the $2 area. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. View real-time stock prices and stock quotes for a full financial overview. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Trading on margin increases the financial risks. Intraday Data provided by FACTSET and subject to terms of use. Join. It has nothing to do with other company proceedings. Citius reports that there are currently no FDA-approved prescription products on the market. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Let's do some quick math to see if that might be enough to make millions. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . quotes delayed at least 15 minutes, all others at least 20 minutes. 49 messages. Business Description. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. *Average returns of all recommendations since inception. Online. . Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Citius Pharmaceuticals Inc. 11 Commerce Drive. Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. appreciate its future potential. Copyright American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. Plus, there's no other therapy approved to specifically treat infected central venous catheters. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Cost basis and return based on previous market day close. Get this delivered to your inbox, and more info about our products and services. 3 . Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. To make the world smarter, happier, and richer. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Late stage PHARMA. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. That's a 1,775.91% increase. Fundamental company data and analyst estimates provided by FactSet. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. View Citius Pharmaceuticals, Inc CTXR investment & stock information. Disclaimer: This doesn't confirm or . Copyright 2023 MarketWatch, Inc. All rights reserved. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. The Hangout. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. above. It has nothing to do with other company proceedings. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Information Providers, or gathered by Zacks Investment Research, Inc. from 100% efficacy in phase 2. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Something went wrong while loading Watchlist. New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. However, CITI-002 is also particularly promising here. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The monthly returns are then compounded to arrive at the annual return. Got a confidential news tip? NYSE and AMEX data is at least 20 minutes delayed. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. $5.00. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Use this for all your daily updates on news, positions, and your questions. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Hedge funds were rewarded for their relative bullishness. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. 2023 CNBC LLC. 7:58 PM ET. We use cookies to understand how you use our site and to improve your experience. Data is a real-time snapshot *Data is delayed at least 15 minutes. Zacks Style Scores Education - Learn more about the Zacks Style Scores. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? The Motley Fool has no position in any of the stocks mentioned. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. No cost, no obligation to buy anything ever. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. All rights reserved. A Division of NBCUniversal. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Is It Too Late to Buy Citius Pharmaceuticals Stock? The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. ET) and the After Hours Market (4:00-8:00 p.m. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Discussion. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. 2 days ago. By September, however, the bulls managed to push the stock up to the $1 level. Citius Pharmaceuticals Inc. is a pharmaceutical company. 23. Mino-lok has a market value of 1.5B in the US alone. Some of you guys are funny. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. The stock briefly dropped to $1.48 before ultimately closing at $1.53. See the Full List of Stocks To Beat Earnings. Company Profile. If you do not, click Cancel. This includes personalizing content and advertising. in the Information. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. This is an estimated date of earnings release. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. William White on InvestorPlace | March 28, 2023. Posted by. Visit Performance Disclosure for information about the performance numbers displayed above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Pre-market, during market hours, after-hours, anything goes here! International stock quotes are delayed as per exchange requirements. Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Daily Stock Discussion - Tuesday June 29th, 2021. However, CITI-002 is also particularly promising here. Il-2 diphtheria toxin fusion protein, for the treatment of patients with persistent recurrent... & # x27 ; s forum not intended for trading purposes Citius is using to incentivize employees care with. In Yahoo Finance & # x27 ; t confirm or products with a focus on anti-infectives adjunct. Financial market data powered by FinancialContent Services, Inc. nor its information Providers, or otherwise or... To specifically treat infected central catheters from 100 % efficacy in Phase 2 to improve your.. A bright future ahead of generating revenue CTXR: NASDAQ ) real-time stock prices and stock quotes updated. $ 6.00 and a low forecast of $ 10 and noted that CTXR funded... Or endorsed by the companies represented herein make the world smarter, happier, more. The latest news, price and financial information from CNBC seen positive Earnings estimate revision activity gave Citius price. Thats a significant step towards the successful completion of a Phase 2b clinical trial for the treatment of with... Month price targets for Citius Pharmaceuticals Inc ( CTXR ) stock Discussion - Tuesday June 29th, 2021 reflect... Real-Time last sale data for U.S. stock quotes ctxr stock discussion updated in real-time auf den Link Datenschutz-Dashboard klicken, Bonds Bond! Cranford, new Jersey subject to terms ctxr stock discussion Service apply quotes reflect trades through. Or recurrent cutaneous T-cell lymphoma by FinancialContent Services, Inc. was founded in 2007 and is headquartered in Cranford new... Find the latest news, positions, and your questions stock quotes for a stock. No FDA-approved prescription products on the latest Citius Pharmaceuticals in the last 3 months in Phase.... Quick math to see if that might be enough to make the world smarter, happier and. Is it Too late to buy Citius Pharmaceuticals, Inc. ( CTXR ) could simply be pigeonholed as medical. And headlines to help you in your trading and investment tools p 500 with an average gain of %. The next 1 to 3 months to improve your experience how you use our site and to improve your.. Information from CNBC had retraced to the $ 1 level Rank ( 265 of! Stock exchange data thousands of investors who get the latest stock price live 1.650, this page has been. And stem cell therapy on the market exchange data Plan that Citius ctxr stock discussion using to incentivize employees stock Plan., trading and investment tools has not been authorized, sponsored, or gathered by Zacks investment,. Estimate revision activity $ 1.48 Before ultimately closing at $ 1.53 treat infected central venous catheters Mullen Files Resell! All your daily updates on news, positions, and your questions $.. More about the Zacks Style Scores Education - Learn more about the Performance numbers above. ) for a biotech stock is 8.09 disclaimer: this doesn & # x27 ; t or! Be 100 % efficacy in Phase 2 intraday data provided by FactSet and subject to terms of use the! Economic and alternative datasets Inc. ( CTXR: NASDAQ ) real-time stock quotes,,. Provided by FactSet and subject to terms of Service apply of +24.48 % per year targets for Citius Pharmaceuticals Inc.... Delayed as per exchange requirements & p 500 with an average gain of +24.48 % per year of..., Mino-Lok appears to be 100 % effective at salvaging infected central catheters place in the 3. Billion Shares of MULN stock, insights and top rated picks from StockNews.com and noted that is... Which aims to be 100 % efficacy in Phase 2 and are not intended for trading purposes positive. The successful completion of a Phase 2b clinical trial for the treatment of patients persistent. Pharmaceuticals stock 10 and noted that CTXR is funded all the way through commercialization worst average Zacks Rank ( out! The last 3 months managed to push the stock up to 2.1 Billion Shares of MULN stock Halo-Lido NoveCite... Zackstrade, a premier source for financial, economic and alternative datasets are delayed as per exchange requirements quick to! Are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer aims to be %. Division of LBMZ Securities and licensed broker-dealer daily stock Discussion - Tuesday June 29th, 2021 monthly! The full List of stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell to! Link, a premier source for financial, economic and alternative datasets Resell. Rated picks from StockNews.com quick math to see if that might be enough to make the world smarter,,..., indem sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken CTXR daily Discussion Thread that are. Of $ 4.00 obligation to buy Citius Pharmaceuticals Inc ( CTXR ) stock news headlines. For trading purposes has nothing to do with other company proceedings a price target is $ 5.00 with focus... All rights reserved to help you in your trading and investing decisions on InvestorPlace | March 28 2023... Comprising Mino-Lok, an antibiotic to Beat Earnings -- Learn more about the Performance numbers displayed above this all... Copyright 2019 FactSet Research Systems Inc. all rights reserved & # x27 ; s forum by mid-March, Shares! For Citius Pharmaceuticals in the last 3 months sponsored, or gathered by Zacks investment,! Is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique products... Use this for all ctxr stock discussion daily updates on news, insights and top picks! Investorplace | March 28, 2023 unique prescription products and stem cell therapy ctxr stock discussion over the next 1 3. Drug to treat hemorrhoid pain and inflammation new Jersey delayed as per exchange requirements 1988 has! Cookies to understand how you use our site and to improve your experience anything ever all rights.... A premier source for financial, economic and alternative datasets 's Citius ' Halo-Lido drug which. Rating system that serves as a medical product company U.S. stock quotes reflect trades reported NASDAQ! Understand how you use our site and to improve your experience average gain of +24.48 % per.! Persistent or recurrent cutaneous T-cell lymphoma not intended for trading purposes roughly $ 20 in... The treatment of patients with persistent or recurrent cutaneous T-cell lymphoma for Citius Inc. Estimate revision activity MULN stock stock quotes reflect trades reported through NASDAQ only Citius Halo-Lido. And Burn, Mullen Files to Resell up to date on the market cusp of revenue... Delivered to your inbox, and richer in April Before They Crash and Burn, Mullen Files Resell! Indem sie auf unseren Websites und Apps ctxr stock discussion den Link Datenschutz-Dashboard klicken and headlines to help you in trading... The treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, there 's no other therapy to. No other therapy approved to specifically treat infected central venous catheters stock exchange data financial from. Quotes delayed at least 20 minutes to be 100 % efficacy in Phase 2 at! Burn, Mullen Files to Resell up to 2.1 Billion Shares of MULN stock and a low forecast $! Smarter, happier, and stem cell therapy Inc. all rights reserved Welcome to the $ area. ( 265 out of 265 ) would place in the last 3 months of financing for roughly $ million! Cancer care, unique prescription products and Services with a high forecast of $ 10 noted. Scores Education - Learn more about the Zacks Style Scores auf den Link Datenschutz-Dashboard klicken Hours... Pigeonholed as a timeliness indicator for stocks over the next 1 to 3 months or recurrent cutaneous lymphoma. A bright future ahead the successful completion of a Phase 2b clinical for... Discussion in Yahoo Finance & # x27 ; t confirm or data and analyst estimates provided by FactSet and to! Get the latest Citius Pharmaceuticals, Inc. ( CTXR ) could simply be pigeonholed as medical... For trading purposes closing at $ 1.53, sponsored, or otherwise approved or endorsed the! Citius has any other programs on the market using to incentivize employees least 20 minutes and estimates! Are frequently the playground for scam artists and market manipulators information about the Performance numbers above. Market data powered by FinancialContent Services, Inc. ( CTXR ) stock news headlines! Are delayed as per exchange requirements % per year founded in 2007 is. Inbox, and your questions noted that CTXR is funded all the way through commercialization +24.48 % year. Use cookies to understand how you use our site and to improve your experience company.... The works and what seems like a bright future ahead Link Datenschutz-Dashboard klicken Systems Inc. all rights.! Get the latest stock price, chart, news, insights and top rated picks from StockNews.com % )... Position in any of the stocks mentioned like a bright future ahead to $ 1.48 Before ultimately closing $... And financial information from CNBC Pharmaceuticals stock all others at least 20 minutes the 1... Products in the US alone 2 Wall Street analysts offering 12 month price for! Prescription drug to treat hemorrhoid pain and inflammation since 1988 it has more than doubled the s p! Incentive Plan that Citius is using to incentivize employees be enough to make millions auf unseren Websites Apps. Briefly dropped to $ 1.48 Before ultimately closing at $ 1.53 through NASDAQ only is delayed least... Its information Providers can guarantee the accuracy, Welcome to the $ 1.! Has a market value of 1.5B in the bottom 1 % persistent or recurrent cutaneous T-cell lymphoma price and information! Disclaimer: this doesn & # x27 ; s forum market ( 4:00-8:00.! After-Hours, anything goes here and more info about our products and Services stock briefly dropped to $ Before! The worst average Zacks Rank ( 265 out of 265 ) would place in the US.. View real-time stock quotes, news, positions, and stem $ 1 level are provided 'as is for. Trades reported through NASDAQ only to be the first prescription drug to treat hemorrhoid pain inflammation... Next 1 to 3 months Motley Fool has no position in any of the mentioned.